pmedpharmФармация и фармакологияPharmacy & Pharmacology2307-92662413-2241Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical Univer10.19163/2307-9266-2023-11-5-412-421pmedpharm-1394Research ArticleОБЗОРЫREVIEWОбзор опыта использования системы проблем, связанных с применением лекарственных препаратов, на примере фармакотерапии остеопорозаReview of publications on drug-related problems investigations in osteoporosis patientshttps://orcid.org/0000-0003-4012-2523ЕгороваЕ. А.EgorovaE. A.

кандидат фармацевтических наук, доцент кафедры базисной и клинической фармакологии Ордена Трудового Красного Знамени Медицинского института им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского». 

295021, Россия, Республика Крым, г. Симферополь, б-р Ленина, д. 5/7

Candidate of Sciences (Pharmacy), Assistant Professor of the Department of Basic and Clinical Pharmacology, Order of the Red Banner of Labour Medical Institute n. a.S.I. Georgievsky of Crimean Federal University n.a. V.I. Vernadsky. 

5/7, Lenin Blvd., Simferopol, Republic of Crimea, Russia, 295021

egorovapharm@mail.ruhttps://orcid.org/0000-0002-8059-7075БейтуллаевА. М.BeitullaevA. M.

аспирант 1-го года обучения, ассистент кафедры базисной и клинической фармакологии Ордена Трудового Красного Знамени Медицинского института им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского».

295021, Россия, Республика Крым, г. Симферополь, б-р Ленина, д. 5/7

1st year postgraduate student, Assistant Professor of the Department of Basic and Clinical Pharmacology, Order of the Red Banner of Labour Medical Institute n. a.S.I. Georgievsky of Crimean Federal University n.a. V.I. Vernadsky.

5/7, Lenin Blvd., Simferopol, Republic of Crimea, Russia, 295021

asan25.2001@gmail.comhttps://orcid.org/0000-0002-6636-3950МатвеевА. В.MatveevA. V.

кандидат медицинских наук, доцент кафедры клинической фармакологии и терапии, руководитель Учебно-образовательного центра фундаментальной и трансляционной медицины ФГБОУ ДПО РМАНПО Минздрава России. 

125993, Россия, г. Москва, ул. Баррикадная, д. 2/1, стр. 1.

Candidate of Sciences (Medicine), Assistant Professor of the Department of Clinical Pharmacology and Therapy n. a. Acad. B.Ye. Votchal, Head of the Academic Educational Centre of Fundamental and Translational Medicine, Russian Medical Academy of Continuing Professional Education. 

Bld. 1, 2/1, Barrikadnaya Str., Moscow, Russia, 125993

avmcsmu@gmail.comhttps://orcid.org/0000-0003-1571-9301КоряноваК. Н.KoryanovaK. N.

кандидат фармацевтических наук, доцент кафедры фармакологии с курсом клинической фармакологии ПМФИ – филиала ФГБОУ ВО ВолгГМУ Минздрава России. 

357532, Россия, г. Пятигорск, пр-кт Калинина, д. 11

Candidate of Sciences (Pharmacy), Assistant Professor of the Department of Pharmacology with a Course of Clinical Pharmacology, Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University. 

11, Kalinin Ave., Pyatigorsk, Russia, 357532

kskor-16@mail.ruОрдена Трудового Красного Знамени Медицинский институт им. С.И. Георгиевского федерального государственного автономного образовательного учреждения высшего образования «Крымский федеральный университет им. В.И. Вернадского»РоссияOrder of the Red Banner of Labour Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. VernadskyRussian FederationФедеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияRussian Medical Academy of Continuing Professional EducationRussian FederationПятигорский медико-фармацевтический институт – филиал федерального государственного бюджетного образовательного учреждения высшего образования «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияPyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical UniversityRussian Federation202329012024115412421Copyright © Егорова Е.А., Бейтуллаев А.М., Матвеев А.В., Корянова К.Н., 20242024Егорова Е.А., Бейтуллаев А.М., Матвеев А.В., Корянова К.Н.Egorova E.A., Beitullaev A.M., Matveev A.V., Koryanova K.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmpharm.ru/jour/article/view/1394

Хронический характер остеопороза (ОП) обосновывает проведение длительной фармакотерапии пациентов, что увеличивает вероятность возникновения нежелательных реакций (НР) при применении лекарственных препаратов (ЛП). Повышение требований к качеству проводимого мониторинга безопасности в рамках осуществления фармаконадзора и выявленные проблемы требуют совершенствования системы контроля качества ЛП.

Цель

Цель. Обзор применения перспективного метода мониторинга безопасности ЛП – системы проблем, связанных с применением ЛП (drug-related problems, DRP), при проведении фармакотерапии ОП.

Материалы и методы

Материалы и методы. Для поиска научных работ российских и зарубежных авторов были использованы следующие базы данных и поисковые системы: PubMed, elibrary.ru, Google Scholar, КиберЛенинка, Российская национальная библиотека. Поиск источников информации осуществляли по следующим ключевым словам и словосочетаниям: «drug-related problems», «проблемы, связанные с применением ЛП», «безопасность применения ЛС», «остеопороз» (в русском и английском варианте, соответственно), а также соответствующих MeSH терминов.

Результаты

Результаты. Рассмотрен опыт применения системы DRP в сфере здравоохранения разных стран, изучены факторы риска возникновения проблем, связанных с применением ЛП, соответствующие вмешательства при выявлении высоких значений DRP. Исследования проблем, связанных с применением ЛП для лечения ОП при проведении комплексной фармакотерапии, позволили определить целесообразность использования данного метода в целях повышения безопасности и эффективности проводимого лечения у пациентов.

Заключение

Заключение. Анализ возникающих DRP позволяет повысить приверженность пациентов к лечению и купировать возникающие НР, что улучшает качество жизни пациентов и повышает результативность проводимой фармакотерапии. Внедрение такого метода исследования безопасности ЛП в систему фармаконадзора Российской Федерации является важным шагом в развитии персонализированной медицины. Дальнейшее изучение проблем, связанных с применением ЛП, у пациентов с ОП также позволит снизить риски, возникающие при проведении комбинированной фармакотерапии.

A chronic form of osteoporosis (OP) substantiates a long-term pharmacotherapy of patients, which increases the risk of adverse drug reactions (ADRs) during the therapy. The enhancement of requirements to the quality of safety monitoring carried out in the context of pharmacovigilance and the newly identified safety problems require an improvement of the system of quality control of medicinal products (MPs).

The aim of the work was to review the application of a new promising method for monitoring the drug safety – the system of Drug-Related Problems (DRP) in the osteoporosis pharmacotherapy.

Materials and methods

Materials and methods. The following databases and search engines were used to retrieve scientific papers by Russian and foreign authors: PubMed, elibrary.ru, Google Scholar, CyberLeninka, Russian National Library. The information sources were searched using the following keywords and word combinations: “drug-related problems”, “drug safety”, “osteoporosis” (in Russian and English, respectively), as well as the corresponding MeSH terms.

Results

Results. The application of DRP system in the health care of different countries was reviewed, and the risk factors of the problems associated with the use of MPs, the appropriate interventions in case of the detection of high DRP values were investigated. The study of the problems associated with the use of MPs for the treatment of OP during the complex pharmacotherapy made it possible to determine the feasibility of using this method to improve the safety and effectiveness of this kind of treatment in patients.

Conclusion

Conclusion. The analysis of emerging DRPs makes it possible to increase patients’ adherence to the treatment and stop the ADRs. This improves the quality of life of patients and increases the effectiveness of pharmacotherapy. The introduction of such a method of the drug safety research into the system of pharmacovigilance of the Russian Federation is an important step in the development of personalized medicine. A further study of problems associated with the use of drugs in OP patients will also help to reduce the risks arising during the combination pharmacotherapy.

проблемысвязанные с применением лекарственных препаратовостеопорознежелательные реакциифармаконадзорdrug-related problemsosteoporosisadverse reactionspharmacovigilanceДанный обзор не имел финансовой поддержки от сторонних организаций.This study did not have financial support from outside organizations.ReferencesБалабанова Р.М., Дубинина Т.В., Демина А.Б., Кричевская О.А. Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015-2016 гг. // Научно-практическая ревматология. – 2018. – Т. 56, № 1. – С. 15–21. DOI: 10.14412/1995-4484-2018-15-21Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. The incidence of usculoskeletal diseases in the Russian Federation over 2015–2016. Rheumatology Science and Practice. 2018;56(1):15–21. DOI: 10.14412/1995-4484-2018-15-21. RussianТитова Л.В., Макарова М.В., Смирнова А.А., Обухова И.В., Иванова С.Н. Эпидемиологическая характеристика болезней костно-мышечной системы // Здравоохранение Российской Федерации. – 2018. – Т. 62, № 1. – С. 13–17. DOI: 10.18821/0044-197Х-2018-62-1-13-17Titova LV, Makarova MV, Smirnova AA, Obukhova IV, Ivanova SN. The epidemiological characteristic of diseases of musculoskeletal system. Healthcare of the Russian Federation. 2018;62(1):13–7. DOI: 10.18821/0044-197Х-2018-62-1-13-17. RussianБалабанова Р.М., Дубинина Т.В. Динамика пятилетней заболеваемости болезнями костно-мышечной системы и их распространенности среди взрослого населения России за 2013–2017 гг // Современная ревматология. – 2019. – Т. 13, № 4. – С. 11–17. DOI: 10.14412/1996-7012-2019-4-11-17Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Modern Rheumatology Journal. 2019;13(4):11–7. DOI: 10.14412/1996-7012-2019-4-11-17. RussianЧелищева М.Ю. Условия труда и заболеваемость болезнями костно-мышечной системы работников металлургов // Медицина труда и промышленная экология. – 2009. – Т. 10. – С. 31–36.Chelishcheva MY. Working conditions and incidence of diseases of the musculoskeletal system of metallurgists. Occupational medicine and industrial ecology. 2009;(10):31–6. RussianОлейникова T.A., Пожидаева Д.Н., Орешко A.Ю. Мониторинг заболеваемости патологиями костно-мышечной системы и соединительной ткани в Российской Федерации // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. – 2019. – Т. 12, № 1 – С. 5–13. DOI: 10.17749/2070-4909.2019.12.1.5-13Oleynikova TA, Pozhidaeva DN, Oreshko AYu. Prevalence survey of musculoskeletal and connective tissue disorders in the Russian Federation. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(1):5–13. DOI: 10.17749/2070-4909.2019.12.1.5-13. RussianConsensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis // Am J Med. – 1993. Vol. 94, No. 6. – P. 646–650. DOI: 10.1016/0002-9343(93)90218-eConsensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–50. DOI: 10.1016/0002-9343(93)90218-eCompston J., Cooper A., Cooper C., Gittoes N., Gregson C., Harvey N., Hope S., Kanis J.A., McCloskey E.V., Poole K.E.S., Reid D.M., Selby P., Thompson F., Thurston A., Vine N.; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis // Arch Osteoporos. – 2017. – Vol. 12. – P. 43. DOI: 10.1007/s11657-017-0324-5Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43. DOI: 10.1007/s11657-017-0324-5Sözen T., Özışık L., Başaran N. An overview and management of osteoporosis // Eur J Rheumatol. – 2017. – Vol. 4. – P. 46–56. DOI: 10.5152/eurjrheum.2016.048Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46–56. DOI: 10.5152/eurjrheum.2016.048Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures // Osteoporos Int. – 2006. – Vol. 17. – P. 1726–1733. DOI: 10.1007/s00198-006-0172-4Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33. DOI: 10.1007/s00198-006-0172-4Кравцов В.И., Ахвердян Ю.Р., Фофанова Н.А. Остеопороз, его распространенность и факторы риска развития в Волгоградской области // Сборник статей международной научно-практической конференции «Современные научные исследования: проблемы и перспективы». – Уфа, 2015. – С. 192–195.Kravtsov VI, Akhverdyan YuR, Fofanova NA. Prevalence and risk factors of osteoporosis in the Volgograd region. Modern scientific research: problems and prospects. Modern scientific research: problems and prospects: Proceedings of the international scientific and practical conference. Ufa; 2015. P. 192–195. RussianФомина Л.А., Зябрева И.А. Эпидемиология остеопороза и остеопении // Тверской медицинский журнал. 2015. – Т. 1. – С. 63–73.Fomina LA, Zyabreva IA. Epidemiology of osteoporosis and osteopenia. Tver Medical Journal. 2015;(1):63–73. RussianВербовой А.Ф., Пашенцева А.В., Шаронова Л.А. Остеопороз: современное состояние проблемы // Терапевтический архив. – 2017. – Т. 89, № 5. – C. 90–97. DOI: 10.17116/terarkh201789590-97Verbovoy AF, Pashentseva AV, Sharonova LA. Osteoporosis: Current state of the art. Terapevticheskii arkhiv. 2017;89(5):90–7. DOI: 10.17116/terarkh201789590-97. RussianЛесняк О.М., Баранова И.А., Белова К.Ю., Гладкова Е.Н., Евстигнеева Л.П., Ершова О.Б., Каронова Т.Л., Кочиш А.Ю., Никитинская О.А., Скрипникова И.А., Торопцова Н.В., Арамисова Р.М. Остеопороз в Российской Федерации: эпидемиология, медико-социальные и экономические аспекты проблемы (обзор литературы) // Травматология и ортопедия России. – 2018. – Т. 24, № 1. – C. 155–168. DOI: 10.21823/2311-2905-2018-24-1-155-16814Lesnyak Lesnyak OM, Baranova IA, Belova KYu, Gladkova EN, Evstigneeva LP, Ershova OB, Karonova TL, Kochish AYu, Nikitinskaya OA, Skripnikova IA, Toroptsova NV, Aramisova RM. Osteoporosis in Russian Federation: epidemiology, socio-medical and economical aspects (review). Traumatology and Orthopedics of Russia. 2018;24(1):155–68. DOI: 10.21823/2311-2905-2018-24-1-155-168. RussianГлаголев С.В., Горелов К.В., Чижова Д.А. Российский фармаконадзор в условиях нового регулирования – итоги двух лет и перспективы // Ремедиум. – 2019. – Т. 3. – С. 8–14. DOI: 10.21518/1561-5936-2019-3-8-14Glagolev SV, Gorelov KV, Chizhova DA. Russian pharmacovigilance in a newly regulated environment: two-year results and prospects. Remedium. 2019;(3):8–14. DOI: 10.21518/1561-5936-2019-3-8-14. RussianОлефир Ю.В., Романов Б.К., Аляутдин Р.Н., Лепахин В.К., Крашенинников А.Е., Шубникова Е.В. Оценка отчетности по фармаконадзору в России // Безопасность и риск фармакотерапии. – 2018. – Т. 6, № 4. – С. 150–154. DOI: 10.30895/2312-7821-2018-6-4-150-154Olefir YuV, Romanov BK, Alyautdin RN, Lepakhin VK, Krasheninnikov AE, Shubnikova EV. Assessment of Pharmacovigilance Reporting in Russia. Safety and Risk of Pharmacotherapy. 2018;6(4):150–4. DOI: 10.30895/2312-7821-2018-6-4-150-154. RussianМатвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И. Применение системы проблем, связанных с лекарственными препаратами (Drug-Related Problems), на примере группы нестероидных противовоспалительных средств // Фармация и фармакология. – 2019. – Т. 7, № 4. – С. 215–223. DOI: 10.19163/2307-9266-2019-7-4-215-223Matveev AV, Krasheninnikov AE, Egorova EA, Konyaeva EI. Application of drug-related problems approach to analysis of non-steroidal anti-inflammatory drugs’ safety. Pharmacy & Pharmacology. 2019;7(4):215–23. DOI: 10.19163/2307-9266-2019-7-4-215-223Pfister B., Jonsson J., Gustafsson M. Drug-related problems and medication reviews among old people with dementia // BMC Pharmacol Toxicol. – 2017. – Vol. 8. – Art. ID: 52. DOI: 10.1186/s40360-017-0157-2Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017;8:52. DOI: 10.1186/s40360-017-0157-2Fog A.F., Kvalvaag G., Engedal K., Straand J. Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway // Scand J Prim Health Care. – 2017. – Vol. 35, No. 4. – P. 329–335. DOI: 10.1080/02813432.2017.1397246Fog AF, Kvalvaag G, Engedal K, Straand J. Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway. Scand J Prim Health Care. 2017;35(4):329–35. DOI: 10.1080/02813432.2017.1397246Ayalew M.B., Megersa T.N., Mengistu Y.T. Drug-related problems in medical wards of Tikur Anbessa specialized hospital, Ethiopia // J ResPharmPract. – 2015. – Vol. 4, No.4. – P. 216–221. DOI: 10.4103/2279-042X.167048Ayalew MB, Megersa TN, Mengistu YT. Drug-related problems in medical wards of Tikur Anbessa specialized hospital, Ethiopia. J ResPharmPract. 2015;4(4):216–21. DOI: 10.4103/2279-042X.167048Матвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И. Ретроспективный анализ карт-извещений о нежелательных реакциях антибиотиков пенициллинового ряда с применением метода системы проблем, связанных с лекарственными препаратами // Фармация и фармакология. – 2020. – Т. 8, № 1. – С. 57–64. DOI: 10.19163/2307-9266-2020-8-1-57-64Matveev AV, Krasheninnikov AE, Egorova EA, Koniaeva EI. Retrospective analysis of adverse drug reaction reporting forms associated with penicillin family antibiotics (pcne-drp 9.0) based on drug-related approach. Pharmacy & Pharmacology. 2020;8(1):57–64. DOI: 10.19163/2307-9266-2020-8-1-57-64Матвеев А.В., Егорова Е.А., Коняева Е.И., Бекирова Э.Ю., Аджимамутова Л.А. Изучение безопасности применения антианемических препаратов с использованием метода системы проблем, связанных с лекарственными препаратами // Фармация и фармакология. – 2021. – Т. 9, № 1. – С. 73–83. DOI: 10.19163/2307-9266-2021-9-1-73-83Matveev AV, Egorova EA, Konyaeva EI, Bekirova EYu, Adjimamutova LA. Study of the safety of antianemic preparations by method of the system of problems related to medicinal preparations. Pharmacy & Pharmacology. 2021;9(1):73–83. DOI: 10.19163/2307-9266-2021-9-1-73-83Чернов А.А., Клейменова Е.Б., Сычев Д.А., Абильмажинова А.А., Яшина Л.П., Отделенов В.А., Пающик С.А. Причины геморрагических осложнений у пациентов стационара, получающих лечебные дозы антикоагулянтов // Клиническая фармакология и терапия. – 2018. – Т. 27, № 5. – С. 23–29. DOI: 10.32756/0869- 5490-2018-5-23-29Chernov AA, Kleymenova EB, Sychev DA, Abilmazhinova AA, Yashina LP, Otdelenov VA, Payushchik SA. Causes of hemorrhagic complications in hospitalized patients receiving therapeutic doses of anticoagulants. Clinical pharmacology and therapy. 2018;27(5):23–9. DOI: 10.32756/0869-5490-2018-5-23-29. RussianPage M.J., McKenzie J.E., Bossuyt P.M. Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M.,Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hróbjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., McGuinness L.A., Stewart L.A., Thomas J., Tricco A.C., Welch V.A., Whiting P., Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews // BMJ. – 2021. – Vol. 372. – Art. ID: n71. DOI: 10.1136/bmj.n71Page MJ, McKenzie JE, Bossuyt PM Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71Rootman I. Drug-related problems and the physician: the Calgary experience // Can Fam Physician. – 1973. – Vol. 19, No. 11. – P. 66–68.Rootman I. Drug-related problems and the physician: the calgary experience. Can Fam Physician. 1973;19(11):66–8.American College of Clinical Pharmacy. The definition of clinical pharmacy // Pharmacotherapy. – 2008. Vol. 28, No. 6. – P. 816–817. DOI: 10.1592/phco.28.6.816American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7. DOI: 10.1592/phco.28.6.816Strand L.M., Morley P.C., Cipolle R.J., Ramsey R., Lamsam G.D. Drug-related problems: their structure and function // DICP. – 1990. – Vol. 24, No. 11. – P. 1093–1097. DOI: 10.1177/106002809002401114Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093–97. DOI: 10.1177/106002809002401114Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., Farrar K., Park B.K., Breckenridge A.M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients // BMJ. – 2004. – Vol. 329, No. 7456. – P. 15–19. DOI: 10.1136/bmj.329.7456.15Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. DOI: 10.1136/bmj.329.7456.15Howard R.L., Avery A.J., Slavenburg S., Royal S., Pipe G., Lucassen P., Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review // Br J Clin Pharmacol. – 2007. – Vol. 63, No. 2. – P. 136–147. DOI: 10.1111/j.1365-2125.2006.02698.xHoward RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136–47. DOI: 10.1111/j.1365-2125.2006.02698.xDelgado Silveira E., Fernandez-Villalba E.M., García-Mina Freire M., Albiñana Pérez M.S., Casajús Lagranja M.P., Peris Martí J.F. Impacto de la Intervención Farmacéutica en el tratamientodel paciente mayor pluripatológico [The impact of Pharmacy Intervention on the treatment of elderly multi-pathological patients] // Farm Hosp. – 2015. – Vol. 39, No. 4. – P. 192–202. DOI: 10.7399/fh.2015.39.4.8329Delgado Silveira E, Fernandez-Villalba EM, García-Mina Freire M, Albiñana Pérez MS, Casajús Lagranja MP, Peris Martí JF. Impacto de la Intervención Farmacéutica en el tratamientodel paciente mayor pluripatológico [The impact of Pharmacy Intervention on the treatment of elderly multi-pathological patients]. Farm Hosp. 2015;39(4):192–202. DOI: 10.7399/fh.2015.39.4.8329. SpanishGuignard B., Bonnabry P., Perrier A., Dayer P., Desmeules J., Samer C.F. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist // Eur J Intern Med. – 2015. – Vol. 26, No. 6. – P. 399–406. DOI: 10.1016/j.ejim.2015.05.012Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26(6):399–406. DOI: 10.1016/j.ejim.2015.05.012Bedouch P., Sylvoz N., Charpiat B., Juste M., Roubille R., Rose F.X., Bosson J.L., Conort O., Allenet B.; French Society of Clinical Pharmacy’s Act-IP© Group. Trends in pharmacists’ medication order review in French hospitals from 2006 to 2009: analysis of pharmacists’ interventions from the Act-IP© website observatory // J Clin Pharm Ther. – 2015. – Vol. 40, No. 1. – P. 32–40. DOI: 10.1111/jcpt.12214Bedouch P, Sylvoz N, Charpiat B, Juste M, Roubille R, Rose FX, Bosson JL, Conort O, Allenet B; French Society of Clinical Pharmacy’s Act-IP© Group. Trends in pharmacists’ medication order review in French hospitals from 2006 to 2009: analysis of pharmacists’ interventions from the Act-IP© website observatory. J Clin Pharm Ther. 2015;40(1):32–40. DOI: 10.1111/jcpt.12214Shanika L.G.T., Coombes J., Perera D., Mohamed F., Coombes I., De Silva H.A., Dawson A.H. Ward-based clinical pharmacists and hospital readmission: a non-randomized controlled trial in Sri Lanka // Bull World Health Organ. – 2018. – Vol. 96. – P. 155–164. DOI: 10.2471/BLT.17.198366. Erratum in: Bull World Health Organ. – 2018. – Vol. 96, No. 5. – Art. ID: 368.Shanika LGT, Coombes J, Perera D, Mohamed F, Coombes I, De Silva HA, Dawson AH. Ward-based clinical pharmacists and hospital readmission: a non-randomized controlled trial in Sri Lanka. Bull. World Health Organ. 2018;96:155–64. DOI: 10.2471/BLT.17.198366. Erratum in: Bull World Health Organ. 2018;96(5):368.Stuhec M., Bratović N., Mrhar A. Impact of clinical pharmacist’s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: A prospective non-randomized study // Sci Rep. – 2019. – Vol. 9, No. 1. – Art. ID: 16856. DOI: 10.1038/s41598-019-53057-wStuhec M, Bratović N, Mrhar A. Impact of clinical pharmacist’s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: A prospective non-randomized study. Sci Rep. 2019;9(1):16856. DOI: 10.1038/s41598-019-53057-wTefera G.M., Zeleke A.Z., Jima Y.M., Kebede T.M. Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study // Drug Healthc Patient Saf. – 2020. – Vol. 12. – P. 71–83. DOI: 10.2147/DHPS.S251200Tefera GM, Zeleke AZ, Jima YM, Kebede TM. Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study. Drug Healthc Patient Saf. 2020;12:71–83. DOI: 10.2147/DHPS.S251200Kaufmann C.P., Stämpfli D., Hersberger K.E., Lampert M.L. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process // BMJ Open. – 2015. – Vol. 5, No. 3. – Art. ID: e006376. DOI: 10.1136/bmjopen-2014-006376Kaufmann CP, Stämpfli D, Hersberger KE, Lampert ML. Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open. 2015;5(3):e006376. DOI: 10.1136/bmjopen-2014-006376Keijsers C.J., Leendertse A.J., Faber A., Brouwers J.R., de Wildt D.J., Jansen P.A. Pharmacists’ and general practitioners’ pharmacology knowledge and pharmacotherapy skills // J Clin Pharmacol. – 2015. – Vol. 55, No. 8. – P. 936–943. DOI: 10.1002/jcph.500Keijsers CJ, Leendertse AJ, Faber A, Brouwers JR, de Wildt DJ, Jansen PA. Pharmacists’ and general practitioners’ pharmacology knowledge and pharmacotherapy skills. J Clin Pharmacol. 2015;55(8):936–43. DOI: 10.1002/jcph.500Freyer J., Hueter L., Kasprick L., Frese T., Sultzer R., Schiek S., Bertsche T. Drug-related problems in geriatric rehabilitation patients after discharge - A prevalence analysis and clinical case scenario-based pilot study // Res Social Adm Pharm. – 2018. – Vol. 14, No. 7. – P. 628–637. DOI: 10.1016/j.sapharm.2017.07.009Freyer J, Hueter L, Kasprick L, Frese T, Sultzer R, Schiek S, Bertsche T. Drug-related problems in geriatric rehabilitation patients after discharge - A prevalence analysis and clinical case scenario-based pilot study. Res Social Adm Pharm. 2018;14(7):628–37. DOI: 10.1016/j.sapharm.2017.07.009Krähenbühl-Melcher A., Schlienger R., Lampert M., Haschke M., Drewe J., Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature // Drug Saf. – 2007. – Vol. 30, No. 5. – P. 379–407. DOI: 10.2165/00002018-200730050-00003Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407. DOI: 10.2165/00002018-200730050-00003Abunahlah N., Elawaisi A., Velibeyoglu F.M., Sancar M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey // Int J Clin Pharm. – 2018. – Vol. 40, No. 2. – P. 360–367. DOI: 10.1007/s11096-017-0585-5Abunahlah N, Elawaisi A, Velibeyoglu FM, Sancar M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40(2):360–7. DOI: 10.1007/s11096-017-0585-5Blix H.S., Viktil K.K., Reikvam A., Moger T.A., Hjemaas B.J., Pretsch P., Vraalsen T.F., Walseth E.K. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals // Eur J Clin Pharmacol. – 2004. – Vol. 60, No. 9. – P. 651–658. DOI: 10.1007/s00228-004-0830-4Blix HS, Viktil KK, Reikvam A, Moger TA, Hjemaas BJ, Pretsch P, Vraalsen TF, Walseth EK. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol. 2004;60(9):651–8. DOI: 10.1007/s00228-004-0830-4Garin N., Sole N., Lucas B., Matas L., Moras D., Rodrigo-Troyano A., Gras-Martin L., Fonts N. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions // Sci Rep. – 2021. – Vol. 11, No. 1. – Art. ID: 883. DOI: 10.1038/s41598-020-80560-2Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, Gras-Martin L, Fonts N. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11(1):883. DOI: 10.1038/s41598-020-80560-2Song S., Guo Y., Yang Y., Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis // Pharmacol Ther. – 2022. – Vol. 237 – Art. ID: 108168. DOI: 10.1016/j.pharmthera.2022.108168Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022;237:108168. DOI: 10.1016/j.pharmthera.2022.108168Khandelwal S., Lane N.E. Osteoporosis: Review of Etiology, Mechanisms, and Approach to Management in the Aging Population // Endocrinol Metab Clin North Am. – 2023. – Vol. 52, No. 2. – P. 259–275. DOI: 10.1016/j.ecl.2022.10.009Khandelwal S, Lane NE. Osteoporosis: Review of etiology, mechanisms, and approach to management in the aging population. Endocrinol Metab Clin North Am. 2023;52(2):259–75. DOI: 10.1016/j.ecl.2022.10.009Zhu Z., Yu P., Wu Y., Wu Y., Tan Z., Ling J., Ma J., Zhang J., Zhu W., Liu X. Sex specific global burden of osteoporosis in 204 countries and territories, from 1990 to 2030: An age-period-cohort modeling study // J Nutr Health Aging. – 2023. – Vol. 27, No. 9. – P. 767–774. DOI: 10.1007/s12603-023-1971-4Zhu Z, Yu P, Wu Y, Wu Y, Tan Z, Ling J, Ma J, Zhang J, Zhu W, Liu X. Sex Specific Global Burden of Osteoporosis in 204 Countries and Territories, from 1990 to 2030: An Age-Period-Cohort Modeling Study. J Nutr Health Aging. 2023;27(9):767–74. DOI: 10.1007/s12603-023-1971-4Compston J.E., McClung M.R., Leslie W.D. Osteoporosis // Lancet. – 2019. – Vol. 393, No. 10169. – P. 364–376. DOI: 10.1016/S0140-6736(18)32112-3Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–76. DOI: 10.1016/S0140-6736(18)32112-3Walker M.D., Shane E. Postmenopausal Osteoporosis // N Engl J Med. – 2023. – Vol. 389, No. 21. – P. 1979–1991. DOI: 10.1056/NEJMcp2307353Walker MD, Shane E. Postmenopausal Osteoporosis. N Engl J Med. 2023;389(21):1979–91. DOI: 10.1056/NEJMcp2307353Dyer S.M., Crotty M., Fairhall N., Magaziner J., Beaupre L.A., Cameron I.D., Sherrington C.; Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group. A critical review of the long-term disability outcomes following hip fracture // BMC Geriatr. – 2016. – Vol. 16, No. 1. – Art. ID: 158. DOI: 10.1186/s12877-016-0332-0Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C; Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group. A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr. 2016;16(1):158. DOI: 10.1186/s12877-016-0332-0Савченко Т.Н., Агаева М.И., Носова Л.А., Шаповалова Ю.О. Профилактика остеопороза у женщин // РМЖ. – 2017. – Т. 12. – С. 879–883.Savchenko TN, Agaeva MI, Nosova LA, Shapovalova YuO. Prevention of osteoporosis in women. RMJ. 2017;12:879–83. RussianOryan A., Sahvieh S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate // Life Sci. – 2021. –Vol. 264. – Art. ID: 118681. DOI: 10.1016/j.lfs.2020.118681Oryan A, Sahvieh S. Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sci. 2021;264:118681. DOI: 10.1016/j.lfs.2020.118681McClung M., Harris S.T., Miller P.D., Bauer D.C., Davison K.S., Dian L., Hanley D.A., Kendler D.L., Yuen C.K., Lewiecki E.M. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday // Am J Med. – 2013. – Vol. 126, No. 1. – P. 13–20.DOI: 10.1016/j.amjmed.2012.06.023McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20. DOI: 10.1016/j.amjmed.2012.06.023Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice // Mayo Clin Proc. – 2008. – Vol. 83, No. 9. – P. 1032–1045. DOI: 10.4065/83.9.1032Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45. DOI: 10.4065/83.9.1032Adler R.A., El-Hajj Fuleihan G., Bauer D.C., Camacho P.M., Clarke B.L., Clines G.A., Compston J.E., Drake M.T., Edwards B.J., Favus M.J., Greenspan S.L., McKinney R. Jr., Pignolo R.J., Sellmeyer D.E. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research // J Bone Miner Res. – 2016. – Vol. 31, No. 1. – P. 16–35. DOI: 10.1002/jbmr.2708Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2016;31(1):16–35. DOI: 10.1002/jbmr.2708Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., Dempster D.W., Ebeling P.R., Felsenberg D., Gagel R.F., Gilsanz V., Guise T., Koka S., McCauley L.K., McGowan J., McKee M.D., Mohla S., Pendrys D.G., Raisz L.G., Ruggiero S.L., Shafer D.M., Shum L., Silverman S.L., Van Poznak C.H., Watts N., Woo S.B., Shane E.; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research // J Bone Miner Res. – 2007. – Vol. 22, No. 10. – P. 1479–1491. DOI: 10.1359/jbmr.0707onjKhosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91. DOI: 10.1359/jbmr.0707onjShane E., Burr D. Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Dempster D., Einhorn T.A., Genant H.K., Geusens P., Klaushofer K., Koval K., Lane J.M., McKiernan F., McKinney R., Ng A., Nieves J., O’Keefe R., Papapoulos S., Sen H.T., van der Meulen M.C., Weinstein R.S., Whyte M.; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research // J Bone Miner Res. – 2010. – Vol. 25, No. 11. – P. 2267–2294. DOI: 10.1002/jbmr.253Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94. DOI: 10.1002/jbmr.253Schilcher J., Michaëlsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft // N Engl J Med. – 2011. – Vol. 364, No. 18. – P. 1728–1737. DOI: 10.1056/NEJMoa1010650Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–37. DOI: 10.1056/NEJMoa1010650Chen W., Zhang H., Jiang J., Zhang X., Ding J., Liu Y., Dang H. Application of comprehensive pharmaceutical care program in identifying and addressing drug-related problems in hospitalized patients with osteoporosis // BMC Health Serv Res. – 2022. – Vol. 22, No. 1. – P. 1438. DOI: 10.1186/s12913-022-08862-xChen W, Zhang H, Jiang J, Zhang X, Ding J, Liu Y, Dang H. Application of comprehensive pharmaceutical care program in identifying and addressing drug-related problems in hospitalized patients with osteoporosis. BMC Health Serv Res. 2022;22(1):1438. DOI: 10.1186/s12913-022-08862-xIlić D., Bukumirić Z., Janković S. Drug-related problems in patients with osteoporosis // Vojnosanit Pregl. – 2016. – Vol. 73, No. 3. – P. 261–265. DOI: 10.2298/vsp140909090iIlić D, Bukumirić Z, Janković S. Drug-related problems in patients with osteoporosis. Vojnosanit Pregl. 2016;73(3):261–5. DOI: 10.2298/vsp140909090iLinden-Lahti C., Takala A., Holmström A.R., Airaksinen M. Applicability of drug-related problem (DRP) classification system for classifying severe medication errors // BMC Health Serv Res. – 2023. – Vol. 23. – Art. ID: 743. DOI: 10.1186/s12913-023-09763-3Linden-Lahti C, Takala A, Holmström AR, Airaksinen M. Applicability of drug-related problem (DRP) classification system for classifying severe medication errors. BMC Health Serv Res. 2023;23:743. DOI: 10.1186/s12913-023-09763-3

The authors declare that there are no conflicts of interest present.